LEVETIRACETAM EG LABO 250 mg, film-coated tablet scored 60 tablets
Active ingredients: (S)-etiracetam
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet scored60 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- LEVETIRACETAM EG LABO 250 mg, comprimé pelliculé sécable
- Pharmaceutical form
- comprimé pelliculé sécable
- Route of administration
- orale
- Presentation description
- plaquette(s) PVC polyéthylène PVDC aluminium de 60 comprimé(s)
- Marketing authorisation holder
- EG LABO - LABORATOIRES EUROGENERICS
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 9 Nov 2022
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
67866017CIP73021529CIP133400930215296Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| LÉVÉTIRACÉTAMcomprimé | 250 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.